About ZyStor Therapeutics
ZyStor Therapeutics is a Healthcare company based in Milwaukee (United States) founded in 2004, and was acquired by BioMarin Pharmaceutical in August 2010. Enzyme replacement therapies for lysosomal storage diseases. ZyStor Therapeutics has raised $8.5 million across 1 funding round from investors including BioMarin Pharmaceutical, Mason Wells and Prolog Ventures. Its focus areas include Life Sciences, Metabolic Diseases and Drugs. Its competitors include NGM Biopharmaceuticals, MannKind Corp and Rhythm Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
ZyStor Therapeutics was founded in 2004 in Milwaukee, United States, focusing on biotechnology for lysosomal storage diseases. Novel enzyme replacement therapies were developed through proprietary Glycosylation Independent Lysosomal Targeting (GILT) technology, which employs a peptide tag for high-affinity binding to the M6P receptor. The lead candidate, ZC-701, targeted Pompe disease with enhanced receptor affinity and surface expression. Operations ceased following acquisition by BioMarin for 115 million in August 2010.
- Headquarters Milwaukee, United States
- Stage Acquired
- SectorsHealthcare
- Website zystor.com
- Acquired by BioMarin Pharmaceutical (Aug 2010)
- Total Equity Funding$8.5M (USD)
in 1 rounds
- Latest Funding Round$8.5M (USD), Series A
Dec 2004
- InvestorsBioMarin Pharmaceutical
& 6 more
- Acquired byBioMarin Pharmaceutical
(Aug 2010)
Funding Insights of ZyStor Therapeutics
ZyStor Therapeutics has successfully raised a total of $8.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.5 million completed in December 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.5M
- Total Rounds 1
- Last Round Series A — $8.5M
- First Round $8.5M
(Dec 2004)
- Investors Count 6
All 1 funding rounds of ZyStor Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2004 | $8.5M | Series A | – | Mason Wells, Venture Investors |
7 investors in total: 7 institutional.
Investors in ZyStor Therapeutics
ZyStor Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include BioMarin Pharmaceutical, Mason Wells and Prolog Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| masonwells.com | ||||
Health-focused venture capital investments are made in US sectors. | prologventures.com | Newark, United States | ||
A venture capital firm focused on life sciences investments. | 2005 | apjohnventures.com | Kalamazoo, United States | |
US private equity investments are managed by Stonehenge Capital. | stonehengecapital.com | Baton Rouge, United States | ||
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia | ventureinvestors.com | Madison, United States | ||
| swib.state.wi.us | ||||
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. | 1997 | biomarin.com | San Rafael, United States |
Investor details for ZyStor Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ZyStor Therapeutics
3 dated milestones of ZyStor Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded ZyStor Therapeutics is founded.
- Funding First funding round of $8.5M.
- Exit Acquired by BioMarin Pharmaceutical.
Competitors of ZyStor Therapeutics
ZyStor Therapeutics has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, MannKind Corp and Rhythm Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies |
Detailed competitors of ZyStor Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ZyStor Therapeutics
The website of ZyStor Therapeutics (zystor.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▼ 51.9% vs previous month
Top companies in Metabolic Diseases
3 companies that operate in the same segment as ZyStor Therapeutics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zystor Therapeutics
Complete news archive for ZyStor Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ZyStor Therapeutics
ZyStor Therapeutics was founded in 2004.
ZyStor Therapeutics is headquartered in Milwaukee, United States. It is registered at Milwaukee, Wisconsin, United States.
ZyStor Therapeutics is a funded company, having raised a total of $8.5M across 1 funding round to date. The company's 1st funding round was a Series A of $8.5M, raised on Dec 2004.
ZyStor Therapeutics was founded in 2004 in Milwaukee, United States, focusing on biotechnology for lysosomal storage diseases. Novel enzyme replacement therapies were developed through proprietary Glycosylation Independent Lysosomal Targeting (GILT) technology, which employs a peptide tag for high-affinity binding to the M6P receptor. The lead candidate, ZC-701, targeted Pompe disease with enhanced receptor affinity and surface expression. Operations ceased following acquisition by BioMarin for 115 million in August 2010.
ZyStor Therapeutics's top competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
ZyStor Therapeutics has 7 investors. Key investors include BioMarin Pharmaceutical, Mason Wells, Prolog Ventures, Apjohn Ventures, and Stonehenge Capital.
Yes. ZyStor Therapeutics was acquired by BioMarin Pharmaceutical in August 2010.